Opko Health, INC

OPKO Health reports Q2 2026 financial results, highlighting revenue growth and improved operating loss, alongside significant advancements in its drug development pipeline.

OPKO Health's 2026 Annual Meeting saw stockholders elect all eleven director nominees, approve the 2026 Equity Incentive Plan, and ratify the appointment of Ernst & Young LLP.

OPKO Health announced its first quarter 2026 financial results, highlighting progress in its clinical pipeline including the initiation of a Phase 1 trial for MDX2301 and MDX2003, alongside a narrowed operating loss.

OPKO Health, Inc. announced the immediate appointment of Dr. Subbarao V. Uppaluri, a former CFO, to its Board of Directors, filling a vacancy.

OPKO Health announced a net loss of $31.3 million for Q4 2025 and a significant revenue decrease, despite advancing multiple pipeline programs and securing a major collaboration with Regeneron.

OPKO Health announced its third-quarter 2025 financial results, reporting a net income of $21.6 million and highlighting significant advancements in its biopharmaceutical pipeline and strategic partnerships.

OPKO Health reports a 4% increase in total revenues for Q2 2026, driven by strong performance in intellectual property and product segments, while net loss narrows significantly.

OPKO Health reported a 17% decrease in total revenues for Q1 2026, primarily due to the divestiture of its oncology diagnostics business, while its pharmaceutical segment saw a 10% revenue increase.

OPKO Health reports Q3 2025 results, highlighting strategic asset sales, increased R&D investment, and a significant reduction in operating loss despite revenue declines in services and products.

OPKO Health, Inc. reported a significantly increased net loss for the second quarter and first half of 2025, primarily driven by substantial interest expenses from debt restructuring and the absence of prior year investment gains, despite operational improvements in its diagnostics segment following asset sales.

OPKO Health's Q1 2025 results show a net loss, with revenue impacted by divestitures and foreign exchange, while a pending sale of oncology assets to Labcorp is expected to close in the second half of 2025.

OPKO Health's Q3 2024 results show a net income of $24.9 million, driven by a gain from the sale of select BioReference assets, despite a decrease in overall revenue.

OPKO Health, Inc. reported a significantly wider net loss of $225.7 million in 2025, despite an improved operating loss and strategic divestitures aimed at streamlining its diagnostics business.

OPKO Health files an amendment to its 2024 annual report to correct an exhibit and include XBRL tagging.

OPKO Health's 2024 10-K filing highlights strategic moves including asset sales and pipeline advancements amidst ongoing financial challenges.

OPKO Health's 2023 10-K filing details financial performance, product updates, and strategic initiatives across its pharmaceutical and diagnostics segments.

Adam Logal, Sr. Vice President, CFO of Opko Health, Inc., reported a transaction in 53,266 shares of common stock on July 24, 2026.

Steven D Rubin, Executive VP-Administration and a Director of Opko Health, Inc., reported a transaction in 53,266 shares of common stock on July 24, 2026.

OPKO Health Director John Paganelli acquired 10,000 shares of common stock at $1.135 per share, increasing his direct beneficial ownership.

OPKO Health Director Subbarao V. Uppaluri acquired 50,000 stock options with an exercise price of $1.17, exercisable from March 2027.

Phillip Frost, CEO and Chairman of OPKO Health, reported the acquisition of 580,000 shares of common stock through indirect holdings on November 21, 2025.

Phillip Frost, CEO and Chairman of OPKO Health, acquired 570,000 shares of common stock through trusts, signaling increased insider confidence.

OPKO Health, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

OPKO Health will hold its annual stockholders meeting virtually on April 23, 2025, to vote on director elections, executive compensation, and the ratification of its accounting firm.

OPKO Health files an amendment to its proxy statement solely to include Inline XBRL tagging in the Pay Versus Performance section, with no other changes to the document.

OPKO Health is asking stockholders to approve an amendment to increase the authorized shares of common stock from 1 billion to 1.25 billion at the upcoming annual meeting on March 28, 2024.

Phillip Frost, M.D. and associated entities have amended their Schedule 13D filing for OPKO Health, Inc., reporting a combined beneficial ownership of approximately 34.1% of the company's outstanding common stock.

Dr. Phillip Frost and affiliated entities updated their beneficial ownership in OPKO Health, Inc. to 32.8% of outstanding common stock.

Dr. Phillip Frost and his affiliated trusts have filed Amendment No. 26 to their Schedule 13D, reaffirming their substantial beneficial ownership of 31.7% in OPKO Health, Inc., primarily due to a change in the issuer's outstanding shares.

Dr. Jane Hsiao's beneficial ownership in OPKO Health, Inc. has decreased to 4.48% from above 5%, triggering a Schedule 13D amendment, primarily due to an increase in the Issuer's total outstanding common stock.

Rubric Capital Management LP and David Rosen have jointly reported a beneficial ownership of 6.03% in OPKO Health, Inc.'s common stock, totaling 47,791,243 shares.

OPKO Health, Inc. has filed a Schedule 13G, disclosing a beneficial ownership of 8.1% of Entera Bio Ltd.'s ordinary shares, totaling 3,685,226 shares, as of March 16, 2025.